Peregrine Pharmaceuticals achieved positive results from a Phase II trial evaluating bavituximab in combination with paclitaxel and carboplatin chemotherapy in patients with advanced breast cancer. In the trial, 74% (34 of 46) of patients achieved an objective tumor response by the end of the treatment period and 9% (4 of 46) achieved a clinical complete response. Median PFS was 6.9 months and median overall survival will be reported once the data matures. The data compared favorably to a separa...